ECRM_1170x120_8-1-17

Par Pharmaceutical

HDA honors drug companies with 2017 DIANA awards

HDA honors drug companies with 2017 DIANA awards

PHOENIX — The Healthcare Distribution Alliance (HDA) this week presented its annual Distribution Industry Awards for Notable Achievements in Healthcare (DIANA) to pharmaceutical manufacturers for supply chain innovation and collaboration. Given at the HDA 2017 Business and Leadership Conference in Phoenix, the DIANA awards honor HDA member manufacturers that develop innovative new products and promotions

Endo wraps up Par Pharma acquisition

Endo wraps up Par Pharma acquisition

DUBLIN, Ireland — Endo International plc has completed its $8.05 billion acquisition of Par Pharmaceutical Holdings Inc. from leading global private investment firm TPG. Endo said Monday that with the closing of the deal, announced in May, its U.S. Generics segment that includes Par Pharmaceutical and Qualitest will be named Par Pharmaceutical, an Endo International

Par Pharmaceutical ships AndroGel generic

Par Pharmaceutical ships AndroGel generic

CHESTNUT RIDGE, N.Y. — Par Pharmaceutical has released testosterone gel 1%, a generic version of AndroGel 1% from AbbVie. Par said Wednesday that its testosterone gel 1% product is available in 2.5g and 5g aluminum foil packets containing 25 mg or 50 mg of testosterone, respectively. The company noted that it previously entered into a

Par ships authorized generic of Megace ES

CHESTNUT RIDGE, N.Y. — Par Pharmaceutical Companies Inc. has released an authorized generic version of Par Specialty Pharmaceutical’s Megace ES oral suspension. Megace ES oral suspension (megestrol acetate) is a progestin indicated for the treatment of anorexia, cachexia or an unexplained significant weight loss in patients diagnosed with AIDS. The generic product is available in

Endo to acquire Par for $8.05 billion

Endo to acquire Par for $8.05 billion

DUBLIN, Ireland — Endo International PLC plans to buy Par Pharmaceutical Holdings Inc. from TPG Capital North America in a deal valued at $8.05 billion. The pharmaceutical companies said Monday that the combination will create a leading specialty pharmaceutical company with a generics business that is one of the industry’s fastest-growing and among the top five by U.S.